Jnana Therapeutics

We're looking forward to joining Otsuka Pharmaceutical Companies (U.S.) at the 2025 ACMG - American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting.

Phenylketonuria (PKU) is one of many rare genetic diseases that are diagnosed in childhood. There continues to be a critical need for a safe and efficacious treatment for PKU, which can cause progressive and severe neurological impairment and neuropsychological complications. At Jnana, we are currently advancing JNT-517 as a potential first-in-class oral treatment for PKU. Learn more about our clinical studies: https://bit.ly/41h4dUQ #RareDiseaseDay

This year marks the 10th anniversary of the International Day of Women + Girls in Science. We recognize and celebrate the contributions of women scientists, including our Jnana team members, who are driving therapeutic innovations. #WomeninScience #WomeninSTEM

We’re excited to share the recipients of our 2024 awards, recognizing team members who have gone above and beyond. Congrats to our entire team on a year of many achievements at Jnana! [Pictured L to R: Susan Cantin, Josh Zweig, Long Nguyen, David Rogers, CPA, Devin Diedrich, Tamanna Asarpota, Frank Wu; not pictured recipients: Alex Fitz, Lea Rosskamp]

Our team enjoyed celebrating this year’s accomplishments at our recent holiday party. We look forward to making more progress toward developing transformative therapies for patients in the year ahead!

We’re excited to share the story of the discovery and early clinical development of JNT-517, our oral small molecule drug candidate being evaluated in PKU, in the peer-reviewed journal JCI Insight. Find the publication here: https://bit.ly/3D2qDR4. Thanks to our team for their work on this publication!

We're excited to share our most recent publication in the journal ACS Chemical Biology. Thanks to our amazing team for their work on this effort.

We’re at the E.S. PKU (European Society for Phenylketonuria and Allied Disorders Treated as Phenylketonuria) Conference this week. Stop by our exhibit table, and don’t miss our poster presentation featuring data on the efficacy and safety of JNT-517 from our Phase 1/2 study in adults with PKU. #ESPKU2024

We are proud to announce that Jnana Therapeutics is now part of Otsuka Pharmaceutical Co., Ltd. Jnana will continue to be based in Boston and operate as a direct subsidiary of Otsuka America, Inc. We look forward to continuing our mission to develop small molecules against challenging-to-drug targets for under-addressed diseases and advancing JNT-517 into a pivotal Phase 3 study for PKU in early 2025. Read more: https://bit.ly/3ZD6b2q #acquisition #pharmaceuticals #biotechnology

Today, we presented clinically meaningful, statistically significant results from the second-dose cohort of the Phase 1/2 clinical trial of JNT-517 in adults with phenylketonuria (PKU) at the Society for the Study of Inborn Errors of Metabolism 2024 Annual Symposium. Based on these positive results, we plan to advance JNT-517 directly into a pivotal Phase 3 study in early 2025. Read more: https://bit.ly/47fmynI #SSIEM24 #clinicaltrials #raredisease #PKU